@prefix this: . @prefix sub: . @prefix np: . @prefix rdf: . @prefix xsd: . @prefix rdfs: . @prefix biolink: . @prefix ns1: . @prefix prov: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubInfo; a np:Nanopublication . } sub:assertion { a biolink:Disease . sub:association rdf:object ; rdf:predicate biolink:treats; rdf:subject ; a rdf:Statement; rdfs:label "Furthermore, the efficacy of trazodone in the treatment of primary insomnia or generalized anxiety disorders alone is weak, and the use of certain anti-depressants over FDA-approved benzodiazepines in anxiety disorders has been shown to be associated with a higher risk of adverse drug events [18, 32]."; biolink:has_population_context sub:context; biolink:provided_by ; biolink:publications ; biolink:relation . sub:context a biolink:Cohort; rdfs:label "adults" . a biolink:Drug . } sub:provenance { sub:assertion prov:generatedAtTime "2021-08-25T17:50:45.275467"^^xsd:dateTime . } sub:pubInfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB"; npx:hasSignature "XlIzEoMDOXf2e/orHMS0laj76kXRHxMw3eXBNzZ+nlayUu13m67uLDC9ZQiJMrB+kU1v/KEzttxDg7a3jdPeAFemej2rkEYvVrFLPh80MWtqqFsZvqpEuUHDBHXV2fkIscvawdN3qFtVE8G+p5MB2+GiTLpcBTwnLezazGPYUH8="; npx:hasSignatureTarget this: . this: prov:generatedAtTime "2021-08-25T17:50:45.275467"^^xsd:dateTime; prov:wasAttributedTo ; ns1:wasCreatedFromTemplate . }